Advanced Life Sciences, of Woodridge, Ill., appointed Richard Wieland executive vice president and chief financial officer.
Allegent Technology Group, of Woodbury, N.Y., appointed Gregori Lebedev to its board.
Altus Pharmaceuticals Inc., of Cambridge, Mass., promoted Alexey Margolin to chief scientific officer.
Anadys Pharmaceuticals Inc., of San Diego, appointed Douglas Williams and Steven Holtzman to its board.
Antares Pharma Inc., of Exton, Pa., appointed Paul Wotton to its board.
BioEnterprise Corp., of Cleveland, appointed Glen Gaughan and Michael Lang to its business development team.
Biolex Inc., of Pittsboro, N.C., appointed Thomas Amick, David Castaldi and Sherill Neff to its board.
BioVisioN AG, of Hannover, Germany, appointed Werner Schafer to its supervisory board.
Callisto Pharmaceuticals Inc., of New York, appointed Stephen Carter to its board.
Cell Therapeutics Inc., of Seattle, added Richard Leigh executive vice president and general counsel.
Chromos Molecular Systems Inc., of Burnaby, British Columbia, appointed Phillip Maples vice president of clinical development and manufacturing, Alan Hardwick vice president of process development and Kathryn Hayashi vice president of finance.
Compugen Ltd., of Tel Aviv, Israel, appointed Noam Shani vice president of biology research and development.
Cryptome Pharmaceuticals Ltd., of Melbourne, Australia, appointed Leodevico Ilag chief scientific officer.
Cytogen Corp., of Princeton, N.J., appointed William Thomas senior vice president and general counsel.
CytoGenix Inc., of Houston, added Frederic Kenirgi to its scientific staff.
Dynavax Technologies Corp., of Berkeley, Calif., appointed Timothy Henn vice president of finance and administration.
Dynogen Pharmaceuticals Inc., of Boston, appointed Jan Egberts chief operating officer.
Embrex Inc., of Research Triangle Park, N.C., appointed David Kelly senior director of product management, Inovocox.